Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
Lancet Oncol
.
2022 Feb;23(2):195-197.
doi: 10.1016/S1470-2045(21)00708-7.
Authors
Georg Pfeiler
1
,
Angela DeMichele
2
,
Amylou C Dueck
3
,
Christian Fesl
4
,
Michael Gnant
5
,
Erica L Mayer
6
Affiliations
1
Department of Gynecology, Medical University of Vienna, Vienna, Austria.
2
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
3
Alliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ, USA.
4
Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
5
Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
6
Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: erica_mayer@dfci.harvard.edu.
PMID:
35114114
PMCID:
PMC8803349
DOI:
10.1016/S1470-2045(21)00708-7
No abstract available
Publication types
Comment
MeSH terms
COVID-19*
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Humans
Pandemics
SARS-CoV-2
Substances
CDK4 protein, human
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Grants and funding
P30 CA015083/CA/NCI NIH HHS/United States
UG1 CA233180/CA/NCI NIH HHS/United States